Wuhan YZY Biopharma Co., Ltd. (HKG:2496)

Wuhan YZY Biopharma Cash Flow Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Net Income	-97.6	-191.7	-188.87	-148.52
Depreciation & Amortization	6.57	7.32	6.94	7.62
Loss (Gain) From Sale of Assets	0.07	0.02	0	0.55
Loss (Gain) From Sale of Investments	-	-1.61	-0.67	-1.26
Stock-Based Compensation	0.48	-	1.58	39.65
Other Operating Activities	-0.45	3.26	2.19	14.81
Change in Inventory	1.51	4.85	-1.71	-0.52
Change in Accounts Payable	7.03	12.52	9.47	0.45
Change in Unearned Revenue	20.44	-2.34	1.8	0.25
Change in Other Net Operating Assets	-38.77	-18.34	-7.44	-11.73
Operating Cash Flow	-100.72	-186.02	-176.7	-98.71
Capital Expenditures	-1.51	-1.93	-1.41	-1.9
Sale of Property, Plant & Equipment	-	-	-	0.05
Investment in Securities	-	48.61	-26.83	-18.24
Other Investing Activities	-3.16	8.13	34.04	0.16
Investing Cash Flow	-4.67	54.81	5.8	-19.93
Short-Term Debt Issued	129.4	89.5	76.5	28
Total Debt Issued	129.4	89.5	76.5	28
Short-Term Debt Repaid	-92	-76.5	-28	-92.07
Long-Term Debt Repaid	-0.3	-0.78	-0.44	-0.41
Total Debt Repaid	-92.3	-77.28	-28.44	-92.48
Net Debt Issued (Repaid)	37.1	12.22	48.06	-64.48
Issuance of Common Stock	-	173.96	200	149.91
Other Financing Activities	-4.08	-9.88	-6.73	-4.4
Financing Cash Flow	33.02	176.29	241.33	81.03
Foreign Exchange Rate Adjustments	1.95	-1.92	-	-
Net Cash Flow	-70.41	43.16	70.44	-37.61
Free Cash Flow	-102.22	-187.95	-178.11	-100.61
Free Cash Flow Margin	-94.81%	-	-7822.31%	-827.14%
Free Cash Flow Per Share	-0.53	-1.01	-1.03	-0.66
Cash Interest Paid	4.08	2.39	2.47	4
Levered Free Cash Flow	-73.78	-68.9	-92.77	-
Unlevered Free Cash Flow	-71.24	-67.4	-91.22	-
Change in Working Capital	-9.79	-3.31	2.12	-11.55

Source: S&P Global Market Intelligence. Standard template. Financial Sources.